Insmed Incorporated

What they do

Insmed commercializes ARIKAYCE for MAC lung disease, approved in the US, Europe and Japan, and BRINSUPRI (brensocatib), approved in the US in August 2025 and in the EU in November 2025 for non-cystic fibrosis bronchiectasis. The company also runs clinical programs including TPIP for PH-ILD, PAH, PPF and IPF, INS1148, brensocatib in hidradenitis suppurativa, and gene therapies INS1201 and INS1202. Operations are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.

Revenue drivers

• BRINSUPRI (brensocatib) — Oral once-daily DPP1 inhibitor for NCFB; generated $309.2M in Q2 2026, up 49% from Q1 2026, and is now the larger of the two commercial products.
• ARIKAYCE (amikacin liposome inhalation suspension) — Inhaled therapy for MAC lung disease sold in the US, Europe and Japan; generated $116.3M in Q2 2026, up 8% year over year, with growth driven primarily by international markets.
• US BRINSUPRI launch — US market drove the sequential growth in BRINSUPRI; the company launched in the US in Q3 2025 and is guiding to $1.25B-$1.40B of BRINSUPRI revenue for 2026.
• International ARIKAYCE — International markets were cited as the primary driver of the 8% ARIKAYCE growth in Q2 2026; 2026 ARIKAYCE guidance is reiterated at $450M-$470M.

Recent performance

Total company revenues were $425.5M for Q2 2026, compared with $107.4M for Q2 2025. Six-month 2026 product revenues were $731.5M versus $200.2M in the first half of 2025. Net loss narrowed to $13.2M in Q2 2026 from $321.7M in Q2 2025, helped in part by a $99.8M favorable change in fair value of contingent consideration. Operating loss was $1.5M in Q2 2026, and six-month net loss was $176.8M. Cash and cash equivalents were $544.8M at June 30, 2026, with $543.5M of long-term debt.

Strategy

Management is focused on building the BRINSUPRI launch, with 2026 BRINSUPRI revenue guidance raised to $1.25B-$1.40B. The company submitted an sNDA to the FDA in July 2026 for ARIKAYCE in newly diagnosed MAC lung disease and plans to review Phase 3b ENCORE data with Japan's PMDA in 2026 for a potential Japanese label expansion. TPIP is being advanced in Phase 3 across PH-ILD (PALM-ILD) and PAH (PALM-PAH), with a PPF Phase 3 planned for the second half of 2026 and an IPF Phase 3 planned for the first half of 2027. Insmed raised its combined peak revenue estimate for its three lead programs to more than $14B: more than $7B for BRINSUPRI, more than $6B for TPIP and more than $1B for ARIKAYCE.

Risks

• Dependence on two products — The company states its prospects are highly dependent on successful commercialization and maintained approval of ARIKAYCE and BRINSUPRI.
• ARIKAYCE accelerated approval — US approval was granted under accelerated approval, and full approval depends on timely completion of a confirmatory post-marketing trial.
• Label expansion and new-market approvals — Insmed may fail to obtain approval for ARIKAYCE in front-line NTM lung disease or for ARIKAYCE and BRINSUPRI in additional markets.
• Reimbursement and market acceptance — Commercial success depends on acceptance by physicians, patients and payors and on obtaining and maintaining adequate reimbursement.

Outlook

Insmed anticipates a regulatory decision for brensocatib in NCFB in Japan in the second half of 2026. It expects a potential ARIKAYCE label expansion in the US and Japan and plans to initiate a Phase 3 TPIP study in PPF in the second half of 2026 and in IPF in the first half of 2027. The company is guiding to 2026 BRINSUPRI revenue of $1.25B-$1.40B and ARIKAYCE revenue of $450M-$470M. It also continues to assess evolving US policies and their effect on the timing of future international commercial launches.